Found 214 articles
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock.
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022.
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Scholar Rock today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab.
CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies
CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing.
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference
Scholar Rock today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023
Scholar Rock announced that the Company granted inducement equity awards covering an aggregate of 285,000 shares of its common stock to two newly hired employees, consisting of inducement stock options to purchase an aggregate of 255,000 shares of common stock and inducement restricted stock units, covering an aggregate of 30,000 shares of its common stock.
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer
Scholar Rock today announced the appointment of Tracey M. Sacco as Chief Commercial Officer.
Adimab Provides 2022 Update on Clinical Pipeline
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.
JPM Day 2: Highlights
1/10/2023Stay on top of what's happening at JPM. BioSpace is covering all the key announcements all week.
Adimab Provides Year-End Update on 2022 Partnership Activities
Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
Scholar Rock today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023.
Exo Therapeutics Appoints Nagesh Mahanthappa as Executive Chair
Exo Therapeutics, Inc. today announced the appointment of Nagesh Mahanthappa, PhD, to Executive Chair.
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference
Scholar Rock today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET).
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock today announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in November 2022.
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress
Scholar Rock today reported financial results and corporate updates for the third quarter ended September 30, 2022.
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy
Scholar Rock today announced early data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation being developed with the aim of overcoming resistance to checkpoint therapy in patients with advanced cancer.
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
Scholar Rock today announced the appointment of Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer.
Scholar Rock to Participate in Upcoming Investor Conferences
Scholar Rock today announced that management will participate in the following upcoming investor conferences.
Spinal Muscular Atrophy Treatment Market Size to Hit USD 18.9 BN by 2030
According to Nova one advisor, the global Spinal Muscular Atrophy Treatment market was valued at USD 3.4 Billion in 2021 and it is expected to hit around USD 18.9 billion by 2030 with a CAGR of 18.7% during the forecast period 2022 to 2030.
Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline
Lipocine Inc. announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papapetropoulos, M.D. Ph.D., has been appointed Lead Director and Chairman of the Board.